Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl
Globe Newswire • Mon Jun 23 2025
ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this arrangement, Optime Care will serve as the exclusive specialty pharmacy provider for dispensing the newly FDA-approved and relaunched Vecamyl (mecamylamine) 2.5 mg tablets to patients
ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) – Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this arrangement, Optime Care will serve as the exclusive specialty pharmacy provider for dispensing the newly FDA-approved and relaunched Vecamyl (mecamylamine) 2.5 mg tablets to patients. Tilde, a pharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, selected Optime Care for its proven track record in program continuity, prior experience with Vecamyl® and Daraprim® and expertise in managing small, specialized patient populations.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.